Chemomab Therapeutics (CMMB) Treasury Shares (2022 - 2023)

Chemomab Therapeutics (CMMB) posted Treasury Shares of -$1.2 million for Q3 2023, little changed on a QoQ basis from -$1.2 million in Q2 2023.

Chemomab Therapeutics (CMMB) Treasury Shares (2022 - 2023) Analysis & Trends

Chemomab Therapeutics' Treasury Shares history runs 2 years deep, the most recent figure standing at -$1.2 million for Q3 2023.

Quarterly Treasury Shares changed N/A year-over-year to -$1.2 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was -$1.2 million (changed N/A YoY) and the FY2022 annual result came in at $1.2 million, changed N/A from the prior year.
Treasury Shares was -$1.2 million for Q3 2023 at Chemomab Therapeutics, roughly flat from -$1.2 million in the prior quarter.
Across five years, Treasury Shares topped out at $1.2 million in Q4 2022 and bottomed at -$1.2 million in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-21,709.08
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	265,401.92
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	19.41 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	5.14 Mn
10	Chemomab Therapeutics	124.14 Mn	113.77 Mn	-	-

Download Data